Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations
This facility manufactures APIs & formulations of oncology and non-oncology products.
This facility manufactures APIs & formulations of oncology and non-oncology products.
Asahi Songwon Colors' shareholding in ALSPL has increased from 78% to 100%
A five-day inspection was concluded successfully with no critical and no major observations raised
Additional capacity broadens Grace’s fine chemical capabilities for API production
The plan is to set up an ultramodern Solvent Recovery Plant for third party purposes
The facility will manufacture Specialty and Fine Chemicals tailored to various applications across industries such as Polymer and Water Treatment facilities
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
BHL will undertake the development and supply of these molecules
Subscribe To Our Newsletter & Stay Updated